GENB (Generate Biomedicines) Operating Margin %: -737.04% (As of Dec. 2025)


GENB Generate Biomedicines Inc GENB
6 GF Score
Price $16.92
! 2 Warning Signs
View Full Analysis

What is Generate Biomedicines Operating Margin %?

Generate Biomedicines GENB +2.18% 6 Operating Margin % is -737.04% as of Dec. 2025. GuruFocus rates GENB with a GF Score™ of 6/100. The stock has 2 warning signs investors should review. Among 942 Biotechnology companies, Generate Biomedicines ranks worse than 75.48% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Generate Biomedicines's Operating Income for the six months ended in Dec. 2025 was $-235.07 Mil. Generate Biomedicines's Revenue for the six months ended in Dec. 2025 was $31.89 Mil. Therefore, Generate Biomedicines's Operating Margin % for the quarter that ended in Dec. 2025 was -737.04%.

The historical rank and industry rank for Generate Biomedicines's Operating Margin % or its related term are showing as below:

GENB' s Operating Margin % Range Over the Past 10 Years
Min: -962.6   Med: -849.82   Max: -737.04
Current: -737.04


GENB's Operating Margin % is ranked worse than
75.48% of 942 companies
in the Biotechnology industry
Industry Median: -86.83 vs GENB: -737.04

Generate Biomedicines's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Generate Biomedicines's Operating Income for the six months ended in Dec. 2025 was $-235.07 Mil.


Generate Biomedicines  (NAS:GENB) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Generate Biomedicines Operating Margin % Related Terms


Generate Biomedicines Operating Margin % Historical Data

* Premium members only.

The historical data trend for Generate Biomedicines's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Generate Biomedicines Operating Margin % Chart

Generate Biomedicines Annual Data
Trend Dec24 Dec25
Operating Margin %
-962.60 -737.04

Generate Biomedicines Semi-Annual Data
Dec24 Dec25
Operating Margin % -962.60 -737.04

GENB vs PVLA, SLBT, NKTR: Operating Margin % Comparison

For the Biotechnology subindustry, Generate Biomedicines's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Generate Biomedicines Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Generate Biomedicines's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Generate Biomedicines's Operating Margin % falls into.


GENB
6GF Score
Generate Biomedicines Inc GENB
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Generate Biomedicines Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Generate Biomedicines's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-235.065 / 31.893
=-737.04 %

Generate Biomedicines's Operating Margin % for the quarter that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=-235.065 / 31.893
=-737.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -737.04% mean?
Generate Biomedicines (GENB) has a Operating Margin % of -737.04% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Generate Biomedicines and its competitors. According to the industry distribution chart, Generate Biomedicines ranks #711 out of 942 companies in the Biotechnology industry, placing it in the top 75.5%.
Is Generate Biomedicines' Operating Margin % too high?
Generate Biomedicines' current Operating Margin % is -737.04%. Based on the distribution chart, Generate Biomedicines ranks #711 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Generate Biomedicines has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Generate Biomedicines' Operating Margin % compare to PVLA and SLBT?
According to the Biotechnology industry distribution chart, Generate Biomedicines ranks #711 out of 942 companies for Operating Margin %. This places Generate Biomedicines in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Generate Biomedicines and its competitors. Generate Biomedicines's current Operating Margin % is -737.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Generate Biomedicines stock overvalued right now?
Generate Biomedicines (GENB) has a current Operating Margin % of -737.04%. The current Operating Margin % is -737.04%. Generate Biomedicines' overall GF Score™ is 6/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Generate Biomedicines (GENB), the current Operating Margin % is -737.04% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Generate Biomedicines Business Description

Address 101 South Street, Suite 900, Somerville, MA, USA, 02143
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score

Get the complete analysis for GENB

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.92
Price